The FDA has developed 2 lists with molecular targets to increase drug development for pediatric cancers; there have been at least 62 cases in 2018 of children who have been affected by a rare paralyzing illness; a recent survey has found that health insurance has failed in its basic function of protecting people from financial ruin in case of costly health issues.
Drug development for pediatric cancer has lagged behind the development of drugs for adults, and the FDA is promoting targets to increase drug development for pediatric cancers. According to the Regulatory Affairs Professionals Society, the FDA has developed 2 lists with molecular targets. One list includes molecular targets that could contribute to at least 1 pediatric cancer. The second list identifies new drugs in development that would be exempt from requirements of pediatric cancer studies. There are 205 targets with 62 that target a gene abnormality, 40 that target a cell lineage determinant, and only 5 eligible for waivers.
There have been at least 62 cases in 2018 of children who have been affected by a rare paralyzing illness. The Associated Press reported that the CDC hasn’t found the cause, but that there has been a pattern of cases every other year, with similar waves in 2014 and 2016. The majority of children have experienced muscle weakness or paralysis after a fever and respiratory illness. Polio and West Nile virus have been ruled out, and most kids recover.
A recent survey has found that health insurance has failed in its basic function of protecting people from financial ruin in case of costly health issues. One-third of the most seriously ill people in the United States in the survey had spent all or most of their savings while sick, according to The New York Times. Respondents had been hospitalized twice in the last 2 years and had seen at least 3 doctors. More than 20% with insurance had trouble paying for basic necessities, and 13% had to borrow money. The survey also found family members who are not sick also feel financial strain.
CMS' 340B Repayment Proposal May Harm Vulnerable Hospitals, Reward Those With Higher Revenues
April 26th 2024The 340B hospitals not receiving an offsetting lump-sum payment from CMS following 2018-2022 cuts later ruled unlawful are disproportionately rural, publicly owned, and nonacademic, according to a new study.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Kaiser Permanente was hit by a data breach in mid-April, impacting 13.4 million health plan members; GlaxoSmithKline (GSK) sued Pfizer and BioNTech for allegedly infringing on its messenger RNA technology patents in the companies’ COVID-19 vaccines; the CDC announced the first-known HIV cases transmitted via cosmetic injections.
Read More